The Other Peptide Tradition

Walk into a pharmacy in Moscow and ask for something to help after a stroke, and among the things behind the counter is a small bottle of nasal drops containing a seven-amino-acid peptide called Semax. It is a registered medicine in Russia, prescribed by neurologists there, and the research programme behind it had already been running for a decade and a half when its originators published a retrospective account of its design and study in 1997 4. Raise the same compound with a consultant in Manchester or Munich and the likeliest response is a blank look. That gap does not exist because Western medicine examined this work and rejected it. It exists because Western medicine has largely never read it: the bulk of the literature is in Russian, in journals with thin international indexing, written to reporting conventions that differ from the ones Anglophone readers are trained on — and it has never been driven through a European or American regulatory submission, which is the one process that would have forced the whole record to be translated, standardised and opened to outside inspection.

Semax is not a one-off. Selank, an anxiolytic peptide developed at the same Moscow institute, is likewise a registered medicine in Russia and nowhere else. A parallel programme, rooted in Leningrad and continuing in St Petersburg, produced peptide preparations drawn from thymus and pineal tissue and followed elderly volunteers taking them across six to eight years 1. None of this is fringe in its own country. It is simply absent from the textbooks, formularies and guidelines that a Western clinician actually consults.

So the interesting question is not whether these compounds work — we will get to why that cannot be answered from here — but how a body of work this large became invisible. The obvious explanations all fail. It was not small: it spans multiple institutes, several decades and a great many publications. It was not secret; most of it was published in the ordinary way. And it was not weighed by outsiders and found wanting, because outsiders mostly never weighed it at all.

A programme that outlasted a country

It helps to picture the shape of the thing. This was not one laboratory following one molecule. Semax and Selank emerged from work associated with the Institute of Molecular Genetics of the Russian Academy of Sciences in Moscow, and with two figures in particular — Igor Ashmarin and Nikolai Myasoedov — whose interest lay in what Russian pharmacology calls regulatory peptides: short sequences, often fragments of larger hormones, that appeared to act on the nervous system without carrying the parent hormone's endocrine effects. Semax is the clearest expression of that idea, built around a fragment of adrenocorticotropic hormone, stripped of the portion that makes the hormone a hormone and stabilised against the enzymes that would otherwise dismantle it within minutes 4.

The second strand ran through Leningrad and then St Petersburg, associated with Vladimir Khavinson and Vyacheslav Morozov, and began from tissue extracts rather than hormone fragments — preparations from thymus and pineal gland, later refined towards short defined sequences. Its organising interest was ageing, and its clinical work was correspondingly long-horizon: the 2003 report that made it best known abroad followed 266 people over sixty across six to eight years 1. Both strands survived the end of the Soviet Union and carried on, which is worth pausing on. Research programmes that run forty years on one idea are rare anywhere, and mostly for reasons of funding rather than merit.

What a bioregulator is supposed to be

The theoretical commitment underneath all of this is where the two traditions genuinely part company, and the difference is conceptual rather than a matter of vocabulary. It would survive translation perfectly intact.

Western pharmacology is organised around targets. A drug is understood as a molecule that binds a specified receptor or enzyme, and the whole development apparatus follows: identify the target, measure affinity, establish a dose-response relationship, show that occupying the target produces the clinical effect. The Russian regulatory-peptide framing starts somewhere else. A bioregulator is conceived as a signal that nudges a physiological system back towards its normal working state — acting, in the language of a 2002 review of the geroprotective strand, on the systems that maintain homeostasis, on tissue-specific protein synthesis and on the regulation of gene expression, rather than on one receptor 6.

That is not a woollier version of the same idea. It is a different idea, and it has consequences. A modulator with no named target, whose effects depend on the state of the system you give it to, is awkward to test in the Western manner. What is the dose-response curve for restoring balance? What is the primary endpoint? It also makes for a difficult dossier, because among the first things a Western regulator wants is a mechanism of action, and "it regulates" is not an answer the form accepts.

Four ways a literature goes missing

Set the theory aside, though, and the practical reasons this work is unreachable are far more mundane than any of it. They are worth taking in order of how much they actually explain.

The first of those does most of the work, and two of the papers cited in this piece illustrate it exactly. The 1997 account of Semax's design 4 and the 1997 clinical study of Semax in acute ischaemic stroke 5 are both indexed internationally and both discoverable by any Western researcher in seconds — and both are in Russian, their titles carried in the square brackets that database convention uses to mark a translation. A reader without Russian gets a title, an abstract of a few hundred words, and a stop. The study is not hidden. It is right there, and it cannot be read.

An access problem is not a quality problem

This distinction is the hinge of the whole piece, and the one most often collapsed. When a reader meets a literature they cannot check, the reflex is to treat inaccessibility as a signal — as though a paper that is hard to reach were thereby likely to be a poor paper. There is no such implication. Every barrier in that table is a fact about distribution, indexing and paperwork; none is a fact about what the underlying experiments found. A study written in Russian is not a worse study for being written in Russian.

Nor does the traffic run only one way. When this work has been done as an international collaboration and submitted to a Western journal, it has been published there like anything else: the 2002 study of the peptide epitalon in a transgenic mouse model of mammary tumour development appeared in the International Journal of Cancer, with Russian and Italian co-authors, and went through the same review as everything else in that issue 3. The channel exists and functions. It is simply narrow.

The limits that are real

Having said that plainly, the limitations deserve to be said just as plainly, because the fair reading of this tradition is not a rescue mission. Independent replication outside Russia is limited, and that matters for the reason it always matters: an effect that survives being handled by strangers is standing on something the originating laboratory did not itself supply. Much of this programme has never had that test, or has had it only in fragments.

The internationally visible portion of the record is also often thin on methodological detail by contemporary standards. The 1997 stroke study set thirty patients receiving Semax alongside intensive therapy against eighty patients of comparable severity on conventional treatment alone, and reported an influence on the rate at which damaged neurological function returned 5. That is a real clinical observation, and it is not a randomised, blinded, placebo-controlled trial; the comparison group was assembled rather than allocated. The long geroprotective cohort work has a similar character — years of follow-up and striking reported differences, arriving in internationally readable form as a summary rather than as a design an outside reader can interrogate 1.

There is a curious asymmetry buried in all this, too. The single result from this tradition that Western readers are most likely to have met — a 2003 report that a short pineal peptide induced telomerase activity and telomere elongation in cultured human cells 2 — usually reaches them stripped of the programme it belongs to, quoted in marketing copy rather than read as one experiment inside a decades-long research effort. The tradition manages to stay invisible even when one of its findings does not.

The dossier nobody outside has seen

And then there is the fact that cuts in both directions at once. A compound registered as a medicine in Russia has, by definition, been through a national approval process. A dossier was assembled. Somebody assessed manufacturing, stability, toxicology and clinical data, and reached a conclusion. That dossier is not a journal article and is not published, so no outside reader has seen it. Which means two things at once, and both have to be held: there may well be substantial evidence about these compounds that is nowhere visible in the literature an outsider can read — and precisely because it is not visible, an outsider cannot judge whether it is any good. Registration elsewhere is not a reason to assume the evidence is strong. It is also not nothing. It is a sealed box, and a sealed box is genuinely different from an empty one.

The verdict that refuses to be one

Which leaves the conclusion, and it is an uncomfortable one to write because it satisfies nobody. A Western reader is not in a position to conclude that these compounds work. The internationally accessible evidence does not carry that weight: too little independent replication, too little methodological detail on the page, too much of the record out of reach. But that same reader is not in a position to conclude that they do not work either. Nothing here has failed. There is no body of negative replications, no collapsed foundation, no trial that came back empty. The absence is an absence of reading, not an absence of results.

So the honest answer is a third one, and it is not a hedge between the other two: this evidence cannot be adequately assessed from outside. That is an unsatisfying place to end, and the discomfort is exactly why people slide off it in one direction or the other — into enthusiasm, because decades of work and a national registration sound like a great deal; or into dismissal, because unfamiliar and unreadable can feel like grounds. Both moves convert a problem about knowledge into a verdict the available knowledge cannot support. The correct response to "I cannot see this well enough to judge it" is to say so and stop, rather than to guess and call the guess a conclusion.

What would change it

Two things would change the picture, and neither of them is exotic.

• Independent replication by groups outside Russia, published in internationally accessible journals — the ordinary mechanism by which any finding becomes portable across borders.
• Full translated dossiers, or the regulatory submissions themselves, opened for outside assessment rather than summarised at second hand.
• Failing either, systematic translation of the primary Russian-language literature would at least let outsiders form a view of the methods — a far smaller intervention, and still nobody's job.

The trouble is that neither of the first two happens without pressure, and the pressure is not there. Replication costs money and confers no advantage on whoever pays for it. A foreign dossier costs a great deal more, and most of these sequences are old, openly described and unpatentable, which removes the commercial sponsor who would otherwise fund one. And a compound already registered in its home market has no reason to seek either: it has a licence, a prescriber base and a supply chain, and everything an outside regulator would demand is pure cost against a market it does not have. The incentives that would make this literature legible to the rest of the world all point the wrong way. That is why it has stayed illegible for forty years, and why it is likely to remain so.